Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
5.13M
-
Shares change
-
-432K
-
Total reported value, excl. options
-
$22.4M
-
Value change
-
-$3.69M
-
Number of buys
-
11
-
Number of sells
-
-18
-
Price
-
$4.36
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q4 2021
39 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2021.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.13M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (3.22M shares), PURA VIDA INVESTMENTS, LLC (517K shares), Ikarian Capital, LLC (395K shares), VANGUARD GROUP INC (219K shares), MILLENNIUM MANAGEMENT LLC (153K shares), BANK OF AMERICA CORP /DE/ (83.8K shares), Pentwater Capital Management LP (71.3K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (66.9K shares), Clearline Capital LP (64.9K shares), and TWO SIGMA ADVISERS, LP (56.7K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.